Antismooth muscle and antiactin antibodies are indirect markers of histological and biochemical activity of autoimmune hepatitis

Hepatology

Volumn 59, Issue 2, 2014, Pages 592-600

  Couto, Claudia A ^a   Bittencourt, Paulo L ^b   Porta, Gilda ^c   Abrantes Lemos, Clarice P ^c   Carrilho, Flair J ^c   Guardia, Bianca D ^c   Cançado, Eduardo L R ^c  

^a FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^b Portuguese Hospital   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN ANTIBODY; ANTINUCLEAR ANTIBODY; AUTOANTIBODY; AZATHIOPRINE; BIOLOGICAL MARKER; CORTICOSTEROID; LIVER CYTOSOL TYPE 1 ANTIBODY; MITOCHONDRION ANTIBODY; PREDNISONE; SMOOTH MUSCLE ACTIN ANTIBODY; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ADVERSE OUTCOME; AGED; ANIMAL CELL; ANTIBODY TITER; ARTICLE; AUTOIMMUNE HEPATITIS; BIOCHEMISTRY; CHILD; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; KIDNEY MICROSOME; LIVER KIDNEY MICROSOME TYPE 1 ANTIBODY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; NONHUMAN; PREDICTOR VARIABLE; PRESCHOOL CHILD; PRIORITY JOURNAL; REMISSION; SCHOOL CHILD; YOUNG ADULT;

ACTINS; ADOLESCENT; ADULT; AGED; ANTIBODIES, ANTI-IDIOTYPIC; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; HEPATITIS, AUTOIMMUNE; HUMANS; LIVER; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUSCLE, SMOOTH; PROGNOSIS; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84893692409     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26666     Document Type: Article

References (30)

1. Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006;354:54-66.
2. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36:479-497.
3. Krawitt EL. Autoimmune hepatitis: classification, heterogeneity, and treatment. Am J Med 1994;96:23S-26S.
4. Vergani D, Alvarez F, Bianchi FB, Cancado EL, Mackay IR, Manns MP, et al. Liver autoimmune serology: a consensus statement from the committee for autoimmune serology of the International Autoimmune Hepatitis Group. J Hepatol 2004;41:677-683.
5. Manns M, Gerken G, Kyriatsoulis A, Staritz M, Meyer zum Buschenfelde KH. Characterisation of a new subgroup of autoimmune chronic active hepatitis by autoantibodies against a soluble liver antigen. Lancet 1987;1:292-294.
6. Ballot E, Homberg JC, Johanet C. Antibodies to soluble liver antigen: an additional marker in type 1 auto-immune hepatitis. J Hepatol 2000;33:208-215.
7. Baeres M, Herkel J, Czaja AJ, Wies I, Kanzler S, Cancado EL, et al. Establishment of standardised SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002;51:259-264.
8. Gregorio GV, McFarlane B, Bracken P, Vergani D, Mieli-Vergani G. Organ and non-organ specific autoantibody titres and IgG levels as markers of disease activity: a longitudinal study in childhood autoimmune liver disease. Autoimmunity 2002;35:515-519.
9. Czaja AJ. Behavior and significance of autoantibodies in type 1 autoimmune hepatitis. J Hepatol 1999;30:394-401.
10. Czaja AJ, Cassani F, Cataleta M, Valentini P, Bianchi FB. Frequency and significance of antibodies to actin in type 1 autoimmune hepatitis. Hepatology 1996;24:1068-1073.
11. Ma Y, Okamoto M, Thomas MG, Bogdanos DP, Lopes AR, et al. Antibodies to conformational epitopes of soluble liver antigen define a severe form of autoimmune liver disease. Hepatology 2002;35:658-664.
12. Czaja AJ, Donaldson PT, Lohse AW. Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. Am J Gastroenterol 2002;97:413-419.
13. Homberg JC, Abuaf N, Bernard O, Islam S, Alvarez F, Khalil SH, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987;7:1333-1339.
14. Muratori L, Cataleta M, Muratori P, Lenzi M, Bianchi FB. Liver/kidney microsomal antibody type 1 and liver cytosol antibody type 1 concentrations in type 2 autoimmune hepatitis. Gut 1998;42:721-726.
15. Alvarez F, Berg PA, Bianchi FB, Bianchi L, Burroughs AK, Cancado EL, et al. International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-938.
16. Cancado EL, Abrantes-Lemos CP, Vilas-Boas LS, Novo NF, Carrilho FJ, Laudanna AA. Thermolabile and calcium-dependent serum factor interferes with polymerized actin, and impairs anti-actin antibody detection. J Autoimmun 2001;17:223-228.
17. Norberg R, Thorstensson R, Utter G, Fagraeus A. F-Actin-depolymerizing activity of human serum. Eur J Biochem 1979;100:575-583.
18. Alvarez F, Bernard O, Homberg JC, Kreibich G. Anti-liver-kidney microsome antibody recognizes a 50, 000 molecular weight protein of the endoplasmic reticulum. J Exp Med 1985;161:1231-1236.
19. Manns MP, Czaja AJ, Gorham JD, Krawitt EL, Mieli-Vergani G, Vergani D, et al. American Association for the Study of Liver Diseases. Diagnosis and management of autoimmune hepatitis. Hepatology 2010;51:2193-2213.
20. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18:998-1005.
21. Gayotto LCC, SBP/SBH C. Visão histórica e consenso nacional sobre a classificação das hepatites crônicas. GED 2000;19:137-140.
22. Desmet VJ, Gerber M, Hoofnafle JH, Manns M, Scheuer PJ. Classification of chronic hepatitis: diagnosis, grading and staging. Hepatology 1994;19:1513-1520.
23. Miyake Y, Iwasaki Y, Kobashi H, Yasunaka T, Ikeda F, Takaki A, et al. Clinical features of type 1 autoimmune hepatitis in adolescence and early adulthood. Hepatol Res 2009;39:241-246.
24. Mehendiratta V, Mitroo P, Bombonati A, Navarro VJ, Rossi S, Rubin R, et al. Serologic markers do not predict histologic severity or response to treatment in patients with autoimmune hepatitis. Clin Gastroenterol Hepatol 2009;7:98-103.
25. Cassani F, Cataleta M, Valentini P, Muratori P, Giostra F, Francesconi R, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997;26:561-566.
26. Vuppalanchi R, Gould RJ, Wilson LA, Unalp-Arida A, Cummings OW, Chalasani N, et al. Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int 2012;6:379-385.
27. Granito A, Muratori L, Muratori P, Pappas G, Guidi M, Cassani F, et al. Antibodies to filamentous actin (F-actin) in type 1 autoimmune hepatitis. J Clin Pathol 2006;59:280-284.
28. Bittencourt PL, Goldberg AC, Cancado EL, Porta G, Carrilho FJ, Farias AQ, et al. Genetic heterogeneity in susceptibility to autoimmune hepatitis types 1 and 2. Am J Gastroenterol 1999;94:1906-1913.
29. Czaja AJ, Souto EO, Bittencourt PL, Cancado EL, Porta G, Goldberg AC, et al. Clinical distinctions and pathogenic implications of type 1 autoimmune hepatitis in Brazil and the United States. J Hepatol 2002;37:302-308.
30. Gregorio GV, Portmann B, Karani J, Harrison P, Donaldson PT, Vergani D, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544-553.